UNITED THERAPEUTICSInsider Trading & SEC Form 4 Analysis
Institutional analysis of internal capital flows based on SEC Form 4 filings.
Automated_Intelligence_Report :: UTHR
Algorithmic analysis of recent insider trading activity for UTHR reveals a bearish posture among the C-suite and board members. Based on the latest SEC Form 4 filings, we have tracked capital events executed by 3 distinct corporate insiders. The aggregate nominal exposure during this reporting cycle reached $58.70M.
Market dynamics show a negative net capital flow of $45.71M when isolating open-market purchases versus open-market sales. The trading volume is heavily weighted towards open-market executions, providing a clearer signal of insider conviction regarding current valuation levels compared to option-based equity grants.
From a microstructural perspective, the most significant liquidity event was a divestment by ROTHBLATT MARTINE A (Officer/Other), which accounts for a major share of the recent outflow. Continuous monitoring of these Tier-1 actors is essential, as their liquidity decisions often precede material corporate events or reflect an informed, asymmetric perspective on the future performance of UTHR.
$58.70M
USD NOMINAL VALUE3
UNIQUE C-SUITE ENTITIES2026.06.30
ISO_8601 FORMATAutomated_Queries :: Frequently Asked Questions
>Is insider buying outweighing selling at UTHR?
Open-market selling volume ($45.71M) currently exceeds buying volume ($0.00M), indicating net liquidation by insiders.
>Who is currently buying UTHR stock?
Our algorithmic tracking of SEC Form 4 filings indicates no significant open-market buying activity by major executives for UTHR in the recent reporting period.
>Are UTHR insiders selling their shares?
Yes, we have tracked $45.71M in recent insider liquidations. The most notable recent seller is ROTHBLATT MARTINE A, who executed the largest single offload.